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HIV Protease Inhibitors:  Advances in Therapy and
Adverse Reactions, Including Metabolic Complications
Daniel R. Kaul, M.D., Sandro K. Cinti, M.D., Peggy L. Carver, Pharm.D.,
and Powel H. Kazanjian, M.D.
Protease inhibitors (PIs) effectively inhibit replication of the human
immunodeficiency virus (HIV), and reduce mortality and prolong survival in
patients with HIV infection.  Newer PIs saquinavir (soft gelatin capsule) and
amprenavir, as well as other PIs, may be effective when administered
twice/day.  Adverse reactions may occur, as well as metabolic complications
and interactions between PIs and other drugs, including other PIs.  The
strategy of combining PIs is based on specific pharmacologic interactions
among the agents.
(Pharmacotherapy 1999;19(3):281–298)
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Summary
Human immunodeficiency virus (HIV)
protease inhibitors (PIs), combined with
nucleoside reverse transcriptase inhibitors
(NRTIs), are potent inhibitors of viral replication
that reduce morbidity and prolong survival in
HIV-infected persons.1–3 Consensus guidelines
recommend that an antiretroviral regimen
including a PI be given to all patients in whom a
significant degree of viremia is present, even
those in the early stages of HIV infection.4–5
Mechanism of Action
The PIs inhibit HIV replication at the
postintegrational level after the virus is
integrated into the host genome in acutely and
chronically infected cells.  The target HIV
protease enzyme, a 99-amino acid homodimer,
cleaves pol-gag polypeptides on the viral
envelope just as the virus buds form the plasma
membrane of the infected host cell.  Protease
inhibitors, competitive inhibitors of this enzyme,
result in the release from infected cells of
immature, noninfectious viral particles.6
Efficacy
Indinavir, Nelfinavir, Ritonavir, and Saquinavir
The four approved HIV PIs—indinavir,
nelfinavir, ritonavir, and saquinavir—are
structurally related (Table 1).  Nelfinavir,
ritonavir, and indinavir in combination with two
NRTIs have dramatic virologic potency, with 2–3
log reduction in plasma HIV RNA viral loads and
improvement in immunologic parameters, and
increases in CD4 counts between 50 and 250
cells/mm3.1, 2, 4, 7
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The assumption that PI-associated suppression
of viremia improves prognosis for patients in the
early or middle stages of HIV infection is
indirectly supported by several studies in which
weak regimens accomplished only moderate
reductions in viral loads.8 These studies, with
regimens that reduced plasma HIV RNA viral
load by 1.0 log, reported a 56% reduction in the
risk of disease progression at 1-year follow-up.8, 9
The assertion that additional clinical benefit is
associated with maximum reduction of viral load
to undetectable levels remains to be documented.
Nevertheless, the goal of achieving and main-
taining an undetectable viral load is justified by
the fact that disease progression is slowest in
patients who have the lowest viral load.10
Clinical trials studying the efficacy of PIs in
persons with later stages of acquired
immunodeficiency syndrome (AIDS) directly
showed a decrease in death and increased time to
first AIDS-defining illness.2, 3 Furthermore,
studies in patients with AIDS identified a decline
in mortality after PIs began to be administered in
clinical practice.  One study of 1255 patients
reported a decline in mortality from 29.4/100
person-years in 1995 to 8.8/100 person-years in
1997, and a decrease in morbidity as evidenced
by decline in frequency of three AIDS-associated
opportunistic infections:  Pneumocystis carinii
pneumonia, Mycobacterium avium complex
infections, and cytomegalovirus retinitis.11
Saquinavir Soft Gelatin Caps
The absolute bioavailability of a 600-mg dose
of saquinavir hard gelatin capsules (hgc;
Invirase) is only 4% in healthy adults, which
limits its effectiveness.12 The soft gelatin capsule
(sgc; Fortovase) has greater bioavailability.  In
one study, the relative bioavailability of
saquinavir-sgc compared with saquinavir-hgc
after a single 600-mg dose was 331% (95% CI
207–530).12 At standard dosages, the area under
the curve from zero to 8 hours at 3 weeks was
7249 ng hour/ml for saquinavir-sgc compared
with 866 ng hour/ml for saquinavir-hgc.
The ability of both saquinavir preparations to
achieve virologic suppression was compared in a
randomized trial of 171 antiviral-naïve patients
(mean baseline CD4 count 448 cells/mm3, viral
load 4.8 log copies/ml) who received either
saquinavir-hgc or saquinavir-sgc with two
NRTIs.13 After 16 weeks of treatment, 80% of
patients taking saquinavir-sgc had an
undetectable viral load (< 400 copies/ml),
compared with only 43% of those receiving
saquinavir-hgc.  Mean reductions in viral load
were 2.0 and 1.6 log copies/ml, and mean
increases in CD4 count were 97 and 115
cells/mm3 in the two groups, respectively.  Thus,
saquinavir-hgc should never be the sole PI in a
combination regimen.
Clinical studies found the efficacy of
saquinavir-sgc to be similar to that of indinavir,
nelfinavir, and ritonavir.  In a randomized study
of 62 antiretroviral-inexperienced patients (mean
baseline CD4 count 310 cells/mm3, viral load 4.9
log copies/ml), viral load was below 400
copies/ml at 24 weeks in 100% of patients taking
saquinavir-sgc with two NRTIs and 100% taking
indinavir with two NRTIs, and was below 50
copies/ml in 90%.14 The mean reduction in viral
load was 2.3 log copies/ml in both groups, and
mean increases in CD4 count were 177 and 93
cells/mm3 in the saquinavir-sgc and indinavir
groups, respectively.
In 42 antiviral-naïve patients (mean baseline
CD4 count 419 cells/mm3, viral load 4.8 log
copies/ml), 91% of those taking saquinavir-sgc
with two NRTIs had undetectable viral loads (<
400 copies/ml).15 At 32 weeks, the mean
reduction was 3.34 log copies/ml, and mean
increase in CD4 count was 209 cells/mm3.
Seventy percent of patients had viral loads below
20 copies/ml.  Thus data support saquinavir-sgc
as first-line PI as part of combination therapy.
Amprenavir
Amprenavir, an investigational PI currently
available on an expanded-access basis, appears to
have potent antiretroviral activity.  In an early
282
Table 1.  Protease Inhibitors, Dosage, and Year Licensed
Agent Brand Name Dose Year Licensed
Saquinavir Invirase 600 mg t.i.d. 1995
Ritonavir Norvir 600 mg b.i.d. 1996
Indinavir Crixivan 800 mg t.i.d. 1996
Nelfinavir Viracept 750 mg t.i.d. 1997
Saquinavir Fortovase 1200 mg t.i.d. 1998
Amprenavir (141W94) Agenerase 1200 mg b.i.d. Investigational
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dose-escalation study of amprenavir monotherapy,
at 4 weeks a dosage of 1200 mg twice/day
reduced viral load 1.95 log copies/ml.16
Amprenavir also was tested in combination with
nucleoside agents.  In 41 antiretroviral-naïve
patients (median CD4 count 756 cells/mm3, viral
load 4.43 log copies/ml) receiving amprenavir
1200 mg twice/day plus abacavir 300 mg
twice/day, viral load was less than 500 copies/ml
in 79% and less than 5 copies/ml in 60% at 24
weeks.17 The mean CD4 count increase was 187
cells/mm3.  In 20 PI- and lamivudine-naïve
patients (median CD4 count 405 cells/mm3, viral
load 4.88 log copies/ml), the combination of
zidovudine, lamivudine, and amprenavir 1200
mg twice/day resulted in a reduction of viral load
of 2.35 log copies/ml and increase in CD4 count
of 177 cells/mm3.18
Amprenavir was tested in dual-PI combinations.
Twenty-seven antiviral naïve patients (mean
baseline CD4 count 420 cells/mm3, viral load
4.09 log copies/ml) received one of four
regimens:  group A, amprenavir 800 mg 3
times/day alone; group B. amprenavir 800 mg 3
times/day plus saquinavir-sgc 800 mg 3
times/day; group C, amprenavir 800 mg 3
times/day plus indinavir 800 mg 3 times/day; and
group D, amprenavir 800 mg 3 times/day plus
nelfinavir 750 mg 3 times/day.19 After 4 weeks of
treatment 13/16 patients had undetectable viral
loads (< 400 copies/ml) with median decreases of
1.74, 2.53, 2.57, and 3.18 log copies/ml,
respectively, in the four groups.
The drug selects for mutations at codon 50
(unique to amprenavir), as well as codons 46 and
47.  In vitro data show that whereas amprenavir-
resistant mutants have decreased sensitivity to
ritonavir, they have increased sensitivity to
saquinavir and indinavir.20 The clinical
significance of this is not known.
Twice/Day Dosing
Studies with twice/day dosing of PIs originally
licensed for 3 times/day dosing were conducted
to improve patient compliance by eliminating the
midday dose.21–28 In a preliminary study, 87
lamivudine- and PI-naïve patients were
randomized to indinavir either standard 3
times/day dosing or 1000 or 1200 mg twice/day.21
At 20 weeks, reductions in viral loads were
comparable.  In a larger trial of 374 patients,
interim analysis at 24 weeks revealed that 91%
and 64%, respectively, of patients receiving
indinavir 3 times/day versus twice/day had
plasma viral loads below 400 copies/ml.  Crixivan
is rapidly absorbed (time to maximum
concentration [Tmax] 0.8 ± 0.3 hrs) and cleared
(half-life 0.8 ± 0.4 hrs).23 The observation that
the low trough may lead to failure of
antiretroviral therapy24 could explain the
superiority of dosing the agent 2 rather than 3
times/day.
Nelfinavir is absorbed more slowly (Tmax 2–4
hrs) and has a longer half-life (3.5–5 hrs) than
indinavir,25 and is thus more likely to be effective
with less frequent dosing.  Two studies evaluated
twice/day dosing of nelfinavir.  Thirty-six
treatment-naïve HIV-infected patients (mean
baseline CD4 count 342 cells/mm3, viral load
5.14 log copies/ml) were randomized to
nelfinavir 1250 mg and 10 to 1000 mg twice/day,
each in combination with two NRTIs.26 After 24
weeks of therapy, 96% of patients in each group
had an undetectable viral load (< 400 copies/ml,
mean reduction 2.2 log copies/ml).  The mean
increase in CD4 count at 24 weeks in the
combined groups was 125 cells/mm3.
Nelfinavir 1250 mg twice/day was compared
with nelfinavir 750 mg 3 times/day, both in
combination with two NRTIs, in 279 PI-naïve
patients (mean baseline CD4 count 388
cells/mm3, viral load 5.3 log copies/ml).27 After
32 weeks of treatment, 93% of patients in both
groups had undetectable viral loads (< 400
copies/ml) and mean decreases of 2.2 and 2.4 log
copies/ml, respectively.  Mean increases in CD4
counts were 181 and 155 cells/mm3, respectively.
Preliminary results of twice/day therapy of
saquinavir-sgc-based regimens are available.  One
hundred eighty-six patients were randomized to
saquinavir-sgc 1200 mg 3 times/day or 1600 mg
twice/day in combination with two NRTIs.28
Baseline CD4 count was 337 cells/mm3 and viral
load 4.7 log copies/ml.  At 16 weeks, viral load
reductions and CD4 increases were similar in the
two study arms.
Although these results are preliminary,
twice/day dosing of nelfinavir or saquinavir-sgc is
an option for patients who cannot tolerate a
midday dose.  More long-term data are available
for nelfinavir than for saquinavir-sgc.  Indinavir
should not be dosed twice/day.  Dual-PI therapy
is another option for these patients.
Adverse Reactions
General
Adverse reactions to PIs are not uncommon
(Table 2).  Headache, gastrointestinal complaints,
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and fatigue occasionally occur during the first
week of treatment, but are transient and usually
resolve within 3 weeks.  To reduce early side
effects, many clinicians give agents individually
in a stepwise fashion.  Resistant viral strains are
unlikely to emerge if the entire combination
regimen is introduced within 1 week.
Because several PIs are therapeutically
equivalent, selection of one must take the
toxicity profile as well as the patient’s symptoms
into account.  For example, nelfinavir should be
avoided in patients who have chronic diarrhea, a
symptom caused more commonly by this agent
than by other PIs.25 The drug also may be
avoided in those who have difficulty swallowing
pills, since it dissolves quickly in saliva.  In
contrast, it would be a rational selection for
patients with preexisting nausea or those about
to undergo chemotherapy, since nausea occurs
less frequently with nelfinavir than with
saquinavir, ritonavir, or indinavir.12, 23, 25, 29
Indinavir may crystallize in the urinary tract
and result in nephrolithiasis.23 Consequently, it
should be avoided in individuals who are unable
to maintain adequate hydration, have congestive
cardiac failure, or have had episodes of
nephrolithiasis.  It also may cause asymptomatic
hyperbilirubinemia.23
Ritonavir may cause circumoral or peripheral
paresthesias and taste perversion.29 Amprenavir
may cause a macular or maculopapular rash,
occurring within 7–12 days of starting therapy, in
18% of patients.  Rash may be more common in
patients concurrently treated with other
antiretrovirals (NRTIs) that also cause rash.
Cessation of therapy was required in 33% of
patients, but rechallenge with a gradually
escalating or full dose was successful.20 The rash
may be serious in 3% of patients and result in
Stevens-Johnson syndrome.  Headache, fatigue,
nausea, vomiting, diarrhea, and circumoral
paresthesia also occur with amprenavir.20
Complications
Several complications of PIs, such as
hyperglycemia,30–36 altered fat distribution,34–42
hyperlipidemia,34, 36, 43–47 renal abnormalities
associated with indinavir,48, 49 and increased
bleeding in hemophiliacs,50–54 were described
after these agents were licensed for use.
Management of these complications is crucial to
allow continued therapy.
Hyperglycemia
Several reports described new-onset
hyperglycemia associated with PIs, in addition to
worsening of existing diabetes mellitus.30–36 In
1997, reports of 83 cases of diabetes mellitus
prompted a labeling revision of PIs to include the
warning of hyperglycemia.  The disorder was
serious in several patients; 27 patients required
hospitalization and 5 developed ketoacidosis.
New-onset or exacerbation of existing
hyperglycemia developed an average of 76 days
after PI treatment was begun.30 In six patients (3
taking saquinavir, 1 ritonavir, 2 nelfinavir), blood
glucose levels were elevated from 300 to 1000
mg/dl.  Five patients achieved control of diabetes
with continued PI therapy.31
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Table 2.  Common Adverse Reactions to Protease Inhibitors
Indinavir23 Ritonavir29 Saquinavir (sgc)12 Nelfinavir25
Adverse Event Amprenavir20 (%) Naïve/experienced (%) Naive/experienced (%) Naive/experienced (%)
Symptoms
Diarrhea + 4.6 12.8/18.3 15.6/19.9 20.0/32.0
Nausea + 11.7 23.1/26.2 17.8/10.6 7.0/2.0
Emesis + 4.1 12.8/15.2 4.4/2.9 –/–
Abdominal pain – 8.7 3.4/7.0 13.3/8.6 –/4.0
Taste perversion – – 10.3/5.4 –/– –/–
Asthenia + 3.6 9.4/14.2 6.7/4.8 1.0/1.0
Circumoral paresthesia + – 2.6/5.9 –/–
Peripheral paresthesia – – 6.0/5.0 –/– –/–
Nephrolithiasis – 4.0 –/– –/– –/–
Rash 18 – –/– –/– –/–
Laboratory abnormalities
› Aspartate aminotransferase – 2.1 6.5/3.8 –/3.0 –/3.0
› Alanine aminotransferase – 3.1 5.6/6.1 1.0/4.0 1.0/2.0
Hyperbilirubinemia – 7.8 –/– –/– –/–
Hypertriglyceridemia + – 1.4/7.9 –/– –/–
+ = Reported, frequency not available; – = frequency less than 2% or not reported.
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Data on long-term management and conse-
quences of PI-induced hyperglycemia are sparse.
In a series of seven patients (6 indinavir, 1
ritonavir), one was free of symptoms without
requiring hypoglycemic treatment, one was well
controlled with oral hypoglycemic agents, two
were well controlled with insulin, and one was
poorly controlled with oral agents.32 In two
others, the PI was discontinued with resolution
of hyperglycemia within 6 weeks.  Ketonuria did
not occur, and one patient was briefly
hospitalized for hyperglycemia.
Three studies found the incidence of new-onset
hyperglycemia in patients receiving PIs to be
low.32–34 In one trial conducted from January
1996–January 1997, the frequency was 0.35/100
person-months (95% CI 0.09–0.90) in a cohort of
290 patients.33 Others calculated a rate of 1% in
1050 patients.32 The incidence of of new or
worsening diabetes mellitus was 2% in 116
patients.34
One study compared the relative effects of PIs
and other antiretroviral agents on serum glucose
levels.35 Glucose and insulin levels were
measured before and after start of antiretroviral
therapy in 24 patients.  In 16 patients the
regimen contained a PI and in 8 it did not.  The
control group consisted of 16 HIV-infected
patients who were untreated or receiving stable
therapy.  Glucose and insulin levels increased 14
± 4 mg/dl and 18.6 ± 9.5 IU/ml, respectively, in
patients receiving the PI, whereas no change in
levels was observed in patients not receiving a PI
and controls.  Cortisol and dihydroepiando-
sterone levels did not change in any group.  The
authors did not determine whether changes in
insulin and glucose levels were direct effects of
PIs or secondary to unknown metabolic changes
associated with the more effective viral
suppression achieved with that regimen.
It was suggested that peripheral insulin
resistance may be the mechanism underlying PI-
associated hyperglycemia.36 Intravenous glucose
tolerance tests were performed in 27 patients
treated with a PI, 7 treatment-naïve patients, and
18 uninfected controls.  Eleven PI-treated
patients had impaired glucose tolerance.  The test
was normal in HIV-negative controls and HIV-
infected, treatment-naïve patients.
Patients receiving PIs should have blood
glucose levels measured periodically and be
instructed to notify a physician if hyperglycemic
symptoms occur.  In our clinic, we measure
fasting blood glucose levels before and 8 weeks
after starting treatment, and every 4 months
thereafter.  This should be done more often when
indicated; for example, in patients with existing
glucose intolerance or those receiving agents that
cause dysglycemias, such as didanosine,
pentamidine, corticosteroids, and megestrol
acetate.55
Due to the importance of PIs in the manage-
ment of HIV infection, administering hypoglycemic
agents while continuing PIs is the preferred
strategy.  Treatment of PI-induced hyperglycemia
is similar to that for non-HIV-infected persons
with type II diabetes mellitus.  The goal is a
normal glycated hemoglobin.  Nutrition
counseling is indicated for all patients.  Those
with mild symptoms who do not require
hospitalization should be treated with an oral
hypoglycemic drug.  Interactions between these
agents and PIs occur, however.  Glyburide and
glipizide are metabolized by the cytochrome
P450 (CYP) 2C9/19 isoenzyme and may have
moderate (1.5–3 x) increases or decreases in
AUCs when coadministered with ritonavir.29 If
ritonavir is given with either of these drugs, the
sulfonylurea should be taken at half the usual
starting dosage, and monitoring for hypo-
glycemia is appropriate.  Significant interactions
between sulfonylureas and other PIs are unlikely
to occur, but have not been specifically
evaluated.12, 23, 25
Metformin decreases hepatic glucose produc-
tion and increases insulin sensitivity; hypoglycemia
does not occur when it is given as monotherapy.
The drug is excreted unchanged in urine, does
not undergo hepatic metabolism, and does not
interact with PIs.56 Because of the risk of lactic
acidosis, serum creatinine above 1.5 mg/dl,
significant liver disease, and preexisting acidosis
are contraindications to metformin.  The agent
should be discontinued in patients who develop
hypoxia or dehydration, and should be withheld
for at least 48 hours after administration of
iodinated contrast material and restarted after
serum creatinine has returned to baseline value.56
Acarbose inhibits intestinal and pancreatic
enzymes responsible for hydrolysis of carbo-
hydrates, resulting in delayed glucose absorption
and lower postprandial serum glucose levels.57 It
is metabolized in the gastrointestinal tract, and
significant interactions with PIs are unlikely to
occur.  Flatulence and diarrhea are the main side
effects,57 and the drug should be avoided in
patients with diarrhea, wasting syndrome, or
other gastrointestinal tract pathology.
Troglitazone decreases insulin resistance and
induces CYP3A4.58 It may consequently lower PI
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levels12, 23, 25, 29 and should not be administered to
patients receiving PIs.
Lipid Changes in HIV-Infected Patients
These patients have higher triglyceride levels
than uninfected persons.  In addition,
triglyceride levels are higher in later stages of
HIV infection than in earlier asymptomatic
stage.59–61 Triglyceride levels in 32 patients with
AIDS, 8 asymptomatic HIV-infected patients, and
17 HIV-negative controls were elevated in 30%,
20%, and less than 5%, respectively.59 Respective
mean triglyceride levels were 231 ± 27, 166 ± 36,
and 91 ± 10 mg/dl.  Hypertriglyceridemia
(triglyceride > 150 mg/dl) occurred in 27/58 HIV-
infected patients,61 and similar findings were
reported by others.60 The mean level was 159 ±
80 mg/dl in HIV-infected patients, compared with
79 ± 53 mg/dl in age- and gender-matched
controls.
There are several possible mechanisms of
hypertriglyceridemia in HIV infected patients.62, 63
Cytokines are associated with hyperlipidemia,64,
65 and a correlation exists between elevated a-
interferon levels in patients with AIDS and
hypertriglyceridemia.62 a-Interferon may act by
decreasing lipoprotein lipase levels with resulting
hypertriglyceridemia.62 In addition, the low-
density lipoprotein B phenotype, which is
associated with hypertriglyceridemia, is 2.5 times
more common in patients with AIDS than in
matched controls63; this may be an additional
mechanism of hypertriglyceridemia.
Hyperlipidemia. Protease inhibitor therapy is a
risk factor for developing significant hyper-
lipidemia.34, 36, 43–47 Both hypertriglyceridemia
and hypercholesterolemia have been reported.  In
one study, lipid concentrations were increased in
41 (33%) of 124 patients receiving PIs, and mean
fasting cholesterol and triglyceride levels were
310 and 1194 mg/dl, respectively.44 Cholesterol
levels of 166 patients treated with PIs, 32 HIV-
infected patients who did not receive PIs, and 47
age- and sex-matched controls were 228 ± 7.7,
174 ± 15.4, and 189 ± 15.4 mg/dl, respectively;
respective triglyceride levels were 292 ± 35.4, 142
± 17.7, and 106.2 ± 8.85 mg/dl.  Both levels were
significantly higher in patients treated with
ritonavir plus saquinavir than in those receiving
indinavir alone (469.1 ± 70.8 and 274.1 ± 23.2
mg/dl vs 221 ± 26.6 and 212.4 ± 23.2 mg/dl).34
In a cohort of 94 patients receiving combination
therapy including a PI, serum triglyceride levels
were more than 95% of the normal range in 66%.
Seventeen of 20 patients treated with ritonavir
and 10/11 treated with ritonavir and saquinavir
had triglyceride levels more than 95% of the
normal range.46
Additional studies suggest that hyperlipidemia
is more common with ritonavir or ritonavir plus
saquinavir than with other PIs.  In premarketing
studies of ritonavir, severe hypertriglyceridemia
(> 1500 mg/dl) occurred in 7.9% of patients with
advanced disease.29 In a trial of combination
therapy with ritonavir and saquinavir, triglyceride
elevations to this level occurred in 11% of patients.43
In premarketing studies, severe hypertriglyceridemia
occurred in less than 2% of patients treated with a PI
other than ritonavir.12, 23, 25
A prospective study identified that abnor-
malities in lipid profiles develop soon after PI
treatment begins.  Serum lipid analysis were
performed in 10 antiretroviral-naïve patients after
combination therapy with two NRTIs and
indinavir was begun.45 Within 1 month of
therapy cholesterol baseline levels of 145.8 ±
24.9 mg/dl increased to 172.5 ± 36 mg/dl, and
triglyceride baseline levels of 95.5 ± 39.2
increased to 142.1 ± 54.4.  In phase III clinical
trials of ritonavir, increases in triglyceride levels
of 70–110 mg/dl in naïve patients and 240 mg/dl
in experienced patients were first noted on day
15 and persisted throughout the 16-week
evaluation (Abbott Laboratories, personal
communication, 1998).
To determine whether these changes in lipid
profiles are due to PIs or are a consequence of
viral suppression, changes in metabolic parameters
were assessed before and after start of a regimen
containing either PI or lamivudine, and in a
control group receiving stable therapy.35
Although overall weight gain did not differ
among the groups, glucose, triglyceride, and
cholesterol levels increased in patients treated
with a PI (14 ± 4 mg/dl, p=0.03; 75 ± 35 mg/dl,
p=0.002; + 51 ± 10 mg/dl, respectively, p<0.001)
but not in the lamivudine-treated or control
group.  Viral suppression was more effective with
PI, and the authors suggested that this is a
possible cause of lipid changes.
Pancreatitis and vascular disease are the major
clinical sequelae of hyperlipidemia.  Whereas
their frequency in patients receiving long-term PI
therapy is unknown, isolated cases have been
reported.  Pancreatitis secondary to hyper-
lipidemia was not identified as an adverse event
in phase III trials of ritonavir or in a trial of
ritonavir-saquinavir that lasted less than 90 weeks
(Abbott Laboratories, personal communication,
286
UPDATE ON HIV PROTEASE INHIBITORS  Kaul et al
1998).  Pancreatitis, however, was reported in
postmarketing surveillance trials in hyper-
lipidemic patients taking ritonavir and saquinavir
in combination.  The duration of PI therapy
before the onset of pancreatitis has not been
reported (Abbott Laboratories, personal
communication, 1998).
Two patients receiving PIs developed premature
coronary artery disease.44 One, a 26-year-old
with a history of tobacco and cocaine use and late-
stage HIV infection (CD4 count < 10 cells/mm3),
developed an occlusive thrombus in the right
coronary artery after beginning ritonavir and
saquinavir.  Lipid profiles were not reported.  The
second patient, a 35-year-old man with a 2-year
history of diabetes mellitus and family history of
heart disease (CD4 count 14 cells/mm3), developed
hypercholesterolemia (475 mg/dl), hypertriglyc-
eridemia (1959 mg/dl), and a right-sided cervical
fat pad after beginning an antiretroviral regimen
containing indinavir.  Occlusion of the left
anterior descending and atherosclerosis of the
right coronary artery were noted on coronary
angiogram performed after chest pain developed.
The long-term risk of vascular disease and
pancreatitis may increase as PIs are administered
for prolonged periods of time.
Management of Lipid Abnormalities. Manage-
ment of PI-induced hypertriglyceridemia and
hypercholesterolemia in HIV-infected persons is
the same as in the general population. Patients
with persistent fasting hyper-triglyceridemia
greater than 1000–1500 mg/dl after dietary
intervention should take lipid-lowering agents to
avoid pancreatitis and vascular disease, even
though the true risk for developing these compli-
cations with a given triglyceride level is not known.
Options for therapy include the fibric acid
derivative gemfibrozil, the HMG coenzyme A
(CoA) reductase inhibitor atorvastatin, and
niacin.  In the Helsinki heart study,66 gemfibrozil
decreased triglyceride levels by 41.4% in middle-
aged men with elevated cholesterol levels.  The
drug’s metabolism has not been well studied, but
may involve the CYP system, and thus plasma
levels of this agent may be increased by PIs,
particularly ritonavir.29 Gemfibrozil has not been
described as an inducer of the CYP system and
thus would not be expected to lower PI levels.67
In a study of 15 PI-treated patients with
hyperlipidemia (mean serum cholesterol 357
mg/dl, mean serum triglyceride 1879 mg/dl),
gemfibrozil 600 mg twice/day resulted in
decreases in mean serum cholesterol to 261
mg/dl and mean serum triglyceride to 1244
mg/dl.47 Six patients failed to respond.
Atorvastatin is more potent in reducing
triglycerides than any other HMG CoA reductase
inhibitor.  The highest reduction noted with
fluvastatin, simvastatin, and lovastatin is 27%
(lovastatin 40 mg twice/day).68 In patients with
primary hypercholesterolemia, atorvastatin
reduced triglycerides by 19% at 10 mg/day, 26%
at 20 mg/day, 29% at 40 mg/day, and 37% at 80
mg/day.69 Atorvastatin is a substrate of CYP3A4
isoenzyme, but has not been described as an
inducer, and thus would not be expected to
reduce PI levels (Warner-Lambert Co., personal
communication, 1998).  Atorvastatin levels are
increased by the CYP3A4 inhibitor erythromycin.70
Protease inhibitors, particularly ritonavir, may be
expected to increase atorvastatin levels.29 No
direct data on the interaction between atorvastatin
and protease inhibitors are available (Warner-
Lambert, personal communication, 1998).  Niacin,
which may achieve a triglyceride reduction of up
to 40%, should be considered a third-line agent.
Adverse reactions to lipid-lowering agents
should be evaluated periodically.  Elevations of
serum transaminase levels greater than 3 times
the upper limit of normal occurred in 0.7% of
patients taking atorvastatin in clinical trials.69
The frequency may be higher in HIV-infected
patients taking other hepatotoxic drugs, and
hepatic transaminase levels should be monitored
before starting therapy, at 6 and 12 weeks, and at
least biannually thereafter.69 Rhabdomyolysis
was associated with HMG CoA reductase
inhibitors.69 Treatment with zidovudine and HIV
infection itself may cause myopathy.71 Thus,
patients should be monitored for myalgias or
weakness, and creatine phosphokinase should be
measured if symptoms occur.  The dosage of
niacin should be titrated slowly to 1 g 3
times/day, with flushing common after each dose.
Glucose intolerance is a contraindication to
niacin, and transaminase levels should be
checked, as with atorvastatin.
Patients with hypercholesterolemia should be
managed according to the National Cholesterol
Education Program Adult Treatment Panel II,
which stratifies treatment decisions and sets
treatment goals based on low-density lipoprotein
levels and risk factors for cardiac disease.72 The
HMG CoA reductase inhibitors are preferred
first-line agents.  Both lovastatin and pravastatin
are metabolized by the CYP3A4 isoenzyme, and
large (> 3 x) increases in their AUCs may occur
when administered with ritonavir.29 The CYP
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isoenzyme responsible for the metabolism of
fluvastatin and simvastatin is unknown, and their
AUCs may be increased by ritonavir.29
Interactions with other PIs would be predicted to
be less, but have not been tested.  As with
atorvastatin, transaminase values should be
routinely monitored and clinical monitoring for
rhabdomyolysis is required.  In patients with
both hypercholesterolemia and hypertriglyc-
eridemia, atorvastatin is the drug of choice.68
As lipid abnormalities have been reported
frequently with ritonavir and ritonavir-
saquinavir,43 changing to an alternative PI may be
required.  In one study, 21 patients with
hyperlipidemia taking indinavir or ritonavir-
saquinavir were switched to nelfinavir.  After 3
months the median triglyceride level decreased
from 328 to 248 mg/dl.  Serum cholesterol levels
did not change.73 In patients with severe or
recurrent pancreatitis or active coronary artery
disease who are refractory to drug therapy or
switching protease inhibitors, It may be
necessary to discontinue PI therapy.
Fat Redistribution. Anecdotal reports of
abnormal fat distribution in patients treated with
PIs were followed by systematic investigations.
Peripheral lipodystrophy characterized by facial
and extremity wasting with or without central
adiposity, lipomatosis (dorsocervical fat pad or
other localized collection of fat), and increased
visceral adiposity were reported.34–42 Seven
patients developed dorsocervical fat pad
enlargement 4–61 weeks after starting PI
therapy.37 No correlation was seen between a
particular PI and this complication.  Based on 24-
hour urine cortisol and dexamethasone
suppression testing, Cushing’s disease was
excluded in all patients.  Histopathologic analysis
of a biopsy specimen from one patient
demonstrated unencapsulated fat.
Other reports described increased abnormal fat
distribution due to PIs.  It occurred in three
patients taking indinavir in a large urban clinic.38
Metabolic and body composition analyses were
performed by dual energy x-ray absorptiometry
(DEXA) in eight patients who developed a
dorsocervical fat pad while receiving
antiretroviral treatment; half were receiving a
PI.39 Patients had a higher trunk fat to total fat
ratio than HIV-infected matched controls.
Cushing’s disease was excluded.
Lipodystrophy was reported in eight patients
2–12 months after indinavir was begun.40 Six
patients experienced facial fat loss that created a
cachectic appearance, and two others noted onset
of central adiposity and loss of fat in the
extremities.  Another study suggested that PIs
may cause increased storage of visceral adipose
tissue compared with total body fat.  This
abnormal distribution may have clinical
consequences, such as abdominal fullness or
bloating.  Visceral adipose tissue was assessed by
computerized tomography (CT) in 10 patients
receiving indinavir who had abdominal fullness,
distention, or bloating, and compared with
patients receiving indinavir who did not have
abdominal symptoms and with HIV-positive
controls.41 The mean ratio of visceral to total
abdominal tissue in the three groups were 0.70
(SD 0.20), 0.59 (0.18), and 0.40 (0.15, p<0.05),
respectively.  Mean triglyceride levels in both
indinavir-treated groups correlated with visceral
to total abdominal tissue ratios (r=0.57, p=0.01);
however, the mean body mass index of the three
groups was similar.
The frequency of abnormalities in lipid
distribution was investigated in a cross-sectional
study in 116 PI-treated patients, 32 PI-naïve, and
47 HIV-negative subjects.34 Extremity and facial
fat wasting with relative central adiposity was
observed in 64% of PI-treated patients and 3% of
PI-naïve HIV infected subjects based on DEXA,
physical examination, and patient history.
Patient reports of fat wasting in the face or
extremities were accepted as evidence of
lipodystrophy, and data were collected
retrospectively from questionnaires in which
patients described events over the previous 12
months.  By the more objective criteria of
regional DEXA, performed in 45 PI-treated and
16 PI-naïve subjects, the former had significantly
less fat mass in the arms, legs, and trunk than the
latter.  Central abdominal fat did not differ.
Lipodystrophy occurred in 26/28 patients treated
with combination ritonavir-saquinavir developed
lipodystrophy, compared with 41/77 indinavir-
treated patients and 7/11 patients treated with
other PIs.  The relative risk for developing
lipodystrophy associated with ritonavir-
saquinavir was 1.70 (1.03–2.80) compared with
indinavir.  The mean duration of PI therapy was
15.2 months for patients with lipodystrophy
compared with 10.9 months for untreated
subjects.  Affected patients actually had weight
loss compared with PI-treated subjects without
lipodystrophy, in addition to significantly higher
triglyceride, cholesterol, insulin, and C-peptide
levels, and insulin resistance scores.
Of 118 HIV-infected women treated with a PI,
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19 reported changes in body habitus.42 With the
exception of increased breast size, alterations in
fat distribution were similar to those in men.
The pathogenesis of lipodystrophy and
hyperlipidemia in PI treated patients is unknown.
One group searched for amino acid homology to
a 12-amino acid sequence in the catalytic region
of the HIV-1 protease inhibitor.  They found a
63% amino acid homology to a region of the low-
density lipoprotein-receptor-related protein
(LRP) and a 58% homology with the carboxy
terminal region of the cytoplasmic retinoic acid-
binding protein type 1 (CRABP-1).  The protein
is involved in production of cis-9-retinoic acid,
which in turn is a regulator of adipocyte function.
The LRP functions to increase hepatic clearance
of serum lipids.  The authors hypothesized that
protease inhibitor-mediated alterations in
functions of CRABP-1 and LRP may explain
metabolic changes observed with PI therapy.
These intriguing theories require further
investigation.74
Management of Fat Redistribution. Manage-
ment of lipodystrophy is challenging.  Options
include changing the PI, growth hormone
therapy, surgery, and exercise.34, 42, 73, 75 To
evaluate the effect of changing protease
inhibitors, 21 patients with hyperlipidemia and
lipodystrophy by visual criteria taking either
indinavir or the combination of ritonavir and
saquinavir were changed to a nelfinavir-based
regimen.73 Visual inspection for lipodystrophy
was performed at 1- to 3-month intervals.  Most
patients (57%) had no change at 3 months, 33%
had partial improvement, and 10% worsened.  A
more objective measurement (DEXA, CT scan)
was not performed, and switched patients were
not compared with patients with lipodystrophy
who continued indinavir or ritonavir-saquinavir.
Another patient experienced improvement but
not resolution of lipodystrophy when ritonavir-
saquinavir was changed to indinavir.34 Human
growth hormone 6 mg/kg/day subcutaneously
was administered to two PI-treated patients with
dorsocervical fat pads, truncal obesity, and
peripheral muscle wasting.75 After 12 weeks of
treatment, the fat pad regressed completely in
one patient, and partially after 6 weeks in the
other.  In two patients, neither exercise nor
weight training resulted in a significant change in
body habitus.42
Metabolic side effects possibly associated with
PIs have generated interest in combination
antiretroviral regimens that achieve durable viral
suppression without PIs.  The combination of
zidovudine, didanosine, and nevirapine, a
nonnucleoside reverse transcriptase inhibitor
(NNRTI), achieved undetectable viral loads
(< 400 copies/ml) in 51% of patients at 1 year.76
Patients in this trial, however, were naïve to all
antiretrovirals and had relatively high CD4
counts (median 395 cells/mm3) and relatively
low viral loads (median 4.25 log copies/ml).  Two
preliminary studies of other protease-sparing
regimens showed promising results.  The
combination of zidovudine, lamivudine, and
indinavir was compared with zidovudine,
lamivudine, and efavirenz, an NNRTI, in 450
patients naïve to PIs, lamivudine, and NNRTIs.77
Baseline CD4 count was 345 cells/mm3 and
plasma HIV RNA viral load was 4.77 log
copies/ml.  At 24 weeks, in an intention-to-treat
analysis, 74.7% of patients in the efavirenz arm
versus 56.2% in the indinavir group had plasma
HIV RNA below 400 copies/ml.
Therapy with three nucleoside agents was
investigated as a possible PI-sparing regimen in
173 treatment-naïve patients with CD4 counts of
438 cells/mm3 and plasma HIV RNA levels of
4.50 log copies/ml.  Patients were randomized to
zidovudine and lamivudine or zidovudine,
lamivudine, and abacavir, an investigational
NRTI.78 At 16 weeks, 75% of patients in the
abacavir-containing arm and 35% in the dual-
therapy arm had plasma HIV RNA levels below
400 copies/ml.  The durability of protease-
sparing regimens is unknown, but preliminary
data are promising.
Patients often experience discomfort with fat
redistribution and may find these changes
cosmetically unacceptable.  Furthermore, visceral
adiposity has been associated with insulin
resistance, dyslipidemia, glucose intolerance,
hypertension, and atherosclerosis.79 Long-term
effects of peripheral lipodystrophy are unknown.
Renal Abnormalities Associated with Indinavir
Crystallization
Early studies estimated the frequency of
indinavir-induced nephrolithiasis to be 4%.23
Nephrolithiasis is a distinct feature of indinavir,
and is caused by crystallization of this agent in
the urinary tract.47 Twelve percent of the drug is
excreted unchanged in urine, and its solubility is
greater than 100 mg/ml at pH below 3.5, but only
0.03 mg/ml at pH 6.0.80, 81 In addition to
nephrolithiasis, indinavir may crystallize in other
locations in the urinary tract; dysuria may occur
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if it develops in the bladder47 and chronic renal
insufficiency if it develops in the renal
parenchyma.48, 49
One patient developed azotemia, pyuria,
proteinuria, and hypertension 28 weeks after
beginning monotherapy with indinavir.  Renal
biopsy revealed interstitial fibrosis with tubular
atrophy and chronic inflammation, with
indinavir-appearing crystals and inflammatory
cells in the collecting ducts.  Hypertension and
pyuria resolved after indinavir was discontinued,
but serum creatinine did not return to baseline.49
In a series of seven indinavir-treated patients
without nephrolithiasis but with flank or back
pain and crystalluria, CT scan of the abdomen
showed bilateral renal parenchymal defects
consistent with indinavir crystallization in the
distal renal tubules.48 In three of these patients
the abnormalities resolved with discontinuation
of therapy.  Urinalysis showed crystalluria
(asymptomatic) in 20% of patients treated with
indinavir; renal biopsies were not performed.  It
is possible that the frequency of chronic renal
insufficiency is uncommon with short-term
therapy, but may increase as these agents are
administered for longer treatment courses.
The decision to discontinue indinavir must be
made on an individual basis.  Hydration, pain
control, and temporary discontinuation of the
drug may be considered as a first approach.  If
this fails, invasive procedures to remove the
calculi are indicated.  In early studies, only 9% of
patients with nephrolithiasis required permanent
discontinuation of therapy.23 If rechallenge with
indinavir is attempted, at least 1.5 L of fluid/day
must be consumed to reduce the risk of renal
calculi.23 Patients with a history of nephro-
lithiasis secondary to indinavir should not be
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Table 3.  Drug Interactions:  Effect of Selected Drugs on Protease Inhibitor Serum Levels
Indinavir Saquinavir Ritonavir Nelfinavir Amprenavir
(substrate of 3A4 ,(substrate of 3A4, inhibitor of 3A4)(substrate ofa, (substrate of 3A4b, (substrate of 3A4,
Drug inhibitor of 3A4) Invirase Fortovase inhibitor of 3A4, 2D6) inhibitor of 3A4) inhibitor of 3A4)
Nevirapine fl AUC 28%c fl AUC 27%c NA fl AUC 11%c fl AUC 46%87 NA
fl AUC 8%88
Delavirdine › AUC 40%89 › AUC 5x89 NA › AUC 60%90 › AUC 92%91 NA
fl metab 50%91
Efavirenz fl AUC 35%92 NA fl AUC 60%d, e fl AUC 20%d › AUC 20%93 fl AUC 37%98
› ind 1 g q8hd fl metab 37%93
Rifampin fl AUC 89%23 fl AUC 80%95 fl AUC 84%17 fl AUC 35%29 fl AUC 82%25 fl AUC 81%24
Contraindicated Contraindicated Contraindicated Contraindicated Contraindicated Contraindicated
Rifabutin fl AUC 32%23 fl AUC 40%95 fl AUC 43%12 Contraindicated29, f fl AUC 32%25 fl AUC 14%82
fl 50% dose rif23 Avoid Avoid fl 50% dose rif25 fl 50% dose rif82
Isoniazid No effect10 NA NA NA NA NA
Ketoconazole › AUC 68%23 › AUC 130%12 NA NA › AUC 35%25,e › AUC 32%96
fl ind 600 mg
q8h23
Fluconazole fl AUC 19%23 NA NA › AUC 12%29 NA NA
Cimetidine, No effect23 › AUC 67%12 NA NA NA NA
ranitidine
Grapefruit fl AUC 26%23 NA NA NA NA NA
juice
TMP-SMX No effect23 NA NA NA NA NA
Clarithro- › AUC 29%23 NA › AUC 177%12 › AUC 12%29 NA NA
mycin
Fluoxetine NA NA NA › AUC 19%29, g NA NA
Recommended dosage adjustments are included.  The table does not include all clinically relevant drug interactions.
NA = not available; ind = indinavir; TMP-SMX = trimethoprim-sulfamethoxazole; rif = rifabutin.
aRitonavir is a substrate of 3A4 > 2D6 > 2C9, 2C19 > > 1A2, 2A6, 2E1.  It is an inducer of glucuronosyl transferases and CYP1A2.
bA4 is responsible for 52% of the metabolism of nelfinavir.
cPersonal communication, Roxane Laboratories, 1998.
dPersonal communication, DuPont Merck, 1998.
eThe manufacturer recommends avoiding saquinavir as sole PI with efavirenz.
fRifabutin 150 mg every other day was suggested in patients taking ritonavir.85
gIncreased adverse events in postmarketing experience.
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treated with the drug if they are unable to
maintain adequate hydration or if nephrolithiasis
recurs.  Exclusion of indinavir, however,
diminishes remaining options for future
treatment with PIs.
Exacerbation of Bleeding in Hemophiliac Patients
Clinicians caring for these patients should be
aware of a number of case reports that link PIs to
increased episodes of spontaneous bleeding.50–54
The Food and Drug Administration (FDA) sent
letters to health care providers in July 1996
regarding this possibility.52 Spontaneous
subcutaneous and joint bleeding occurred in a
number of patients with previously stable
bleeding histories soon after starting ritonavir or
indinavir. In one patient bleeding recurred after
withdrawal and resumption of ritonavir, but did
not occur after indinavir was begun.50
The Canadian Adverse Drug Reaction
Newsletter reported 55 cases of increased
episodes of spontaneous bleeding worldwide.51
No serious or life-threatening episodes of
bleeding have occurred, and most hemophiliacs
are able to receive PIs.52 Nonetheless, they
should be alerted to the possibility of increased
bleeding.
Drug Interactions
General
All PIs are substrates of and metabolized by the
CYP3A4 isoenzyme.12, 20, 23, 25, 29 Ritonavir has a
high affinity for additional CYP isoforms (3A >
2D6 > 2C9, 2C19 > > 2A6, 1A2, 2E1).29
Theoretically, drugs that induce CYP3A4 should
lower PI serum levels and thus promote viral
resistance to the agent.  In fact, pharmacokinetic
studies demonstrated that rifampin and rifabutin,
agents that induce CYP, significantly reduce PI
levels (Table 3).82–86 In addition, serum levels of
both drugs are increased by PIs (Table 4).86
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Table 4.  Drug Interactions:  Effect of Protease Inhibitors on Serum Levels of Selected Drugs
Ritonavir
Indinavir Saquinavir (substrate ofa, Nelfinavir Amprenavir
(substrate of 3A4, (substrate of 3A4, inhibitor of 3A4)inhibitor of 3A4,)(substrate of 3A4,b (substrate of 3A4,
Drug inhibitor of 3A4) Invirase Fortovase 2D6 inhibitor of 3A4) inhibitor of 3A4)
Nevirapine fl < 10% Cminc fl AUC 3%c NA No effectc No effect88 NA
Delavirdine No effect89 fl 15% AUC89 NA No effect fl 42% AUC91 NA
Efavirenz No effect92 NA NA NA NA NA
(investigational)
Rifampin Contraindicated Contraindicated Contraindicated Contraindicated Contraindicated Contraindicated
Rifabutin › AUC 204%23 NA, fl 50% dose NA, fl 50% dose › AUC 4x83 › AUC 207%25 › Cmin 3–6 x82
fl 50% dose rif23 rif12 rif12 Contra- fl 50% dose rif25 fl 50% dose rif82
Avoid Avoid indicated29, d
Norethindrone › AUC 26%23, e NA NA fl AUC 40%29, e fl AUC 18%25, e NA
Ethinyl estradiol › AUC 24%23, e fl AUC 47%25, e
TMP-SMX › AUC 19%23 NA NA fl AUC 20%29 NA NA
No change23 fl AUC 20%29
Ketoconazole NA No effect95 NA NA NA › AUC 44%96
Fluconazole No effect23 NA NA NA NA NA
Isoniazid › AUC 13%23 NA NA NA NA NA
Clarithromycin › AUC 53%23 NA › AUC 45%12 › AUC 77%29, f NA NA
14-OH metabolite fl AUC 22%12 fl AUC 100%29
Theophylline NA NA NA fl AUC 43%29 NA NA
Desipramine NA NA NA › AUC 145%29 NA NA
Consider fl dose29
Recommended dosage adjustments are included.  The table does not include all clinically relevant drug interactions.
NA = not available; rif = rifabutin; TMP-SMX = trimethoprim-sulfamethoxazole.
aRitonavir is a substrate of 3A4 > 2D6 > 2C9, 2C19 > > 1A2, 2A6, 2E1.  It is an inducer of glucuronosyl transferases and CYP1A2.
b3A4 is responsible for 52% of the metabolism of nelfinavir.
cPersonal communication, Roxane Laboratories, 1998.
dRifabutin 150 mg every other day was suggested in patients taking ritonavir.85
eAlternative or additional method of contraception is recommended.
fAdjust clarithromycin dosage for patients with renal impairment.
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Thus, rifampin is contraindicated with all PIs.
The dosage of rifabutin, which does not induce
CYP as strongly as rifampin,85 should be reduced
if administered with PIs.  As rifabutin lowers
saquinavir levels more than it does those of other
PIs, this combination should be avoided if at all
possible.12, 23, 25, 29, 83
Recommendations are available for tuber-
culosis therapy in patients treated with PIs.84
The CYP inducers carbamazepine, phenobarbital,
phenytoin, and dexamethasone should be
avoided in patients receiving PIs.  Pharmaco-
kinetic studies with these agents have not been
conducted.
Protease inhibitors, in addition to being
metabolized by CYP3A4, may inhibit this
enzyme; this is accomplished most avidly by
ritonavir, less so by indinavir, nelfinavir, and
amprenavir; saquinavir is the least efficient
inhibitor.20 Thus, drugs that are extensively
metabolized by CYP3A4, such as nonsedating
antihistamines terfenadine and astemizole and
others such as cisapride, may have significant
increases in plasma concentrations when
coadministered with PIs.12 To avoid life-
threatening arrhythmias, these drugs should not
be coadministered with PIs.12, 25, 29
Inhibition of many CYP isoenzymes by
ritonavir accounts for the greater number of
clinically significant drug interactions associated
with this PI.  In addition, the drug may increase
the activity of glucuronosyl transferases, resulting
in loss of therapeutic effect from directly
glucuronidated agents.  A list of predicted drug
interactions with ritonavir is beyond the scope of
this article and is available from the
manufacturer.29
The NNRTIs such as nevirapine and efavirenz
may induce CYP3A4, whereas others, such as
delavirdine, may inhibit this enzyme.
Consequently, PI plasma levels may be influenced
by NNRTIs.  Combinations of these agents,
although not currently recommended as first-line
therapy, are prescribed with increasing frequency
in clinical practice in several situations.
Examples are treatment of those who fail a PI-
containing regimen and PI-naive patients heavily
pretreated with NRTIs.
Although efficacy data on combination NNRTI-
PI therapy are not available to guide dosage
adjustments, pharmacokinetic studies have been
conducted for many such combinations.  The
dosage of indinavir should be increased to 1 g 3
times/day when given in combination with
efavirenz; saquinavir should not be the sole PI in
combination with efavirenz.  Data are conflicting
regarding the interaction of nelfinavir and
nevirapine.  A pharmacokinetic study of eight
HIV-positive patients showed a 46% reduction in
nelfinavir AUC when nevirapine was added.87 A
similar study of 12 patients treated with
stavudine and nelfinavir showed an insignificant
8% decrease in AUC when nevirapine was
added.88 The conflicting results in these two
studies may be explained by the institution of
nevirapine in the first study 2 days after
nelfinavir was begun.  Nelfinavir levels decline
20–30% in the first week of therapy as a result of
autoinduction of CYP3A4 (Roxane Laboratories,
personal communication, 1998).
Indinavir levels are decreased when the drug is
coadministered with nevirapine, and subjects
with higher baseline levels tend to have a larger
reduction.  Thus, the manufacturer does not
currently recommend increasing the dosage of
indinavir (Roxane Laboratories, personal
communication, 1998).  Delavirdine significantly
increases nelfinavir levels and decreases the levels
of an active metabolite.91 In a pharmacokinetic
study in 24 healthy volunteers, 4 subjects
developed neutropenia.  Two subjects had grade
3 or 4 neutropenia, and all resolved within a few
days of stopping the agent.91 If this combination
is prescribed, monitoring for neutropenia is
appropriate.  In a study of patients treated with
delavirdine and saquinavir in combination,
hepatocellular enzyme were elevated in 13% (6%
grade III-IV).95
The only clinically significant drug interaction
identified between NRTIs and PIs is impairment
of indinavir’s absorption by the buffer contained
in didanosine.  If administered together, the two
should be taken at least 1 hour apart on an empty
stomach.23 As nelfinavir, ritonavir, and
saquinavir all should be taken with food,12, 25, 29
they should not be taken with didanosine, which
must be taken one half-hour before or 2 hours
after eating.
Interactions Between PIs
Because ritonavir is a potent inhibitor of the
CYP3A4 system, the plasma concentration of
saquinavir increases 20-fold when the two agents
are given in combination (Table 5).97, 98 When
saquinavir-sgc 1200 mg 3 times/day is combined
with nelfinavir or indinavir, saquinavir AUCs are
increased 392% and 620%, respectively.99
Efficacy data for dual-PI combinations are
outlined below.
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Dual-PI Regimens
The pharmacokinetic interactions outlined
above have been used as a basis for double-
protease inhibitor combination regimens.  Dual-
PI therapy was investigated with goals of
increasing the potency of single PIs, developing
synergy between PIs, and avoiding PI toxicities
by giving lower dosages than prescribed for
single-PI therapy.  Efficacy data for many studies
investigating dual-PI combinations ritonavir-
saquinavir,43, 99, 103–109 nelfinavir-saquinavir-sgc,97,
98, 110–112 indinavir-nelfinavir,113 ritonavir-
nelfinavir,114 and indinavir-ritonavir115 are
outlined below.  At present, most clinicians do
not consider these to be initial regimens in
antiviral-naïve patients and reserve them as
second-line therapy when and if the first single-
PI regimen fails.
Ritonavir-Saquinavir
Ritonavir and saquinavir, the initial dual PI,
was investigated in several trials.  In one study,
136 PI-naïve patients (CD4 count 360 cells/mm3)
had reductions in viral load of 2.7–3.0 log
copies/ml after 12 weeks of treatment.99 In a
subsequent trial, 141 PI-naïve patients (mean
baseline CD4 count 277 cells/mm3, viral load
4.60 log copies/ml) were treated with one of four
ritonavir-saquinavir-hgc regimens:  400-400 mg
twice/day; 600-400 mg twice/day; 400-400 mg 3
times/day; and 600-600 mg twice/day.43 After 60
weeks, 79 (90%) of 88 patients had an
undetectable viral load (< 200 copies/ml) with a
mean decrease in viral load of 2.3 log copies/ml.
The mean increase in CD4 count at 60 weeks was
174 cells/mm3 There were no significant
differences in efficacy among treatments.
Because of reduced toxicity, the 400-400 mg
twice/day regimen was preferred.
Ritonavir-saquinavir-hgc 400-400 mg twice/day
was administered alone or with stavudine 40 mg
twice/day in 208 PI- and stavudine-naïve patients
(mean baseline CD4 count 270 cells/mm3, viral
load 4.3 log copies/ml).103 After 48 weeks of
treatment, 79% in the two-drug group and 83%
in the three-drug group had undetectable viral
loads (< 400 copies/ml).  The mean increase in
CD4 count was 130 cells/mm3 in both groups.
Eighteen PI-naïve patients with advanced
disease (mean baseline CD4 count 12 cells/mm3,
viral load 5.25 log copies/ml) received ritonavir-
saquinavir-hgc 600-600 mg twice/day.104 After 13
weeks, only 22% had an undetectable viral load
(< 100 copies/ml); however, the median decrease
was 2.04 log copies/ml and the median increase
in CD4 count was 19 cells/mm3.  Another study
investigated 58 HIV-infected patients (median
CD4 count 140 cells/mm3, viral load 4.8 log
copies/ml; 64% antiretroviral naive) who were
treated with ritonavir-saquinavir-hgc 600-600 mg
twice/day.105 Eighty-nine percent were given an
NRTI; 38% of these patients were taking a new
NRTI to which they had never been exposed.
After 28 weeks the median decrease in viral load
was 2.1 log copies/ml and the median increase in
CD4 count was 120 cells/mm3.  Viral load was
undetectable in 50% of patients (< 500
copies/ml).  Sixty-seven percent of PI-naïve and
27% of PI-experienced patients achieved an
undetectable viral load between 21 and 28 weeks.
Several small studies examined the
effectiveness of this combination and new NRTIs
as salvage therapy in 21 patients who failed
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Table 5.  Dual-Protease Inhibitor Interactions (effect of drug in first column on drug in each column heading)
Saquinavir
Drug Indinavir Invirase Fortovase Ritonavir Nelfinavir Amprenavir
Indinavir — NA › AUC 620%99 No effect100, a › AUC 83%23, 27, b › AUC 64%20
Invirase NA — — No effect NA NA
Fortovase No effect5 — — No effect12, c › AUC 18%12, d NA
Ritonavir › AUC up to 480%100, a › AUC 1587%12 › AUC 20x99, c — › 1.5x25 NA
Nelfinavir › AUC 53%25, 27, b › AUC 5–30x101, 102 › AUC 392%99, d No effect — NA
Amprenavir No effect20, e NA NA NA NA —
NA = not available.
aIndinavir 400 mg every 12 hours with ritonavir 400 mg every 12 hours likely results in similar serum levels to standard dosing.
bIndinavir 1000 mg every 12 hours coadministered with nelfinavir 750 mg every 12 hours results in serum AUC levels similar to standard
dosing, nelfinavir trough levels may be lower.
cNo difference in actual plasma exposures when ritonavir is coadministered with the same dosage of either Invirase or Fortovase.  The
recommended dosage is 400–600 mg twice/day for both agents with ritonavir.
dSuggested dosage is Fortovase 800 mg 3 times/day with nelfinavir 750 mg 3 times/day.
eComparable with historical controls.
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initial therapy with either indinavir or nelfinavir
(defined by a detectable viral load after 16 weeks
of therapy).106 After 33 weeks, 71% of patients
failing indinavir had viral loads of fewer than 400
copies/ml.  Viral loads at the time of the switch
were 4.13 and 4.25 log copies/ml among
responders and nonresponders, respectively.
Twenty-one patients failing initial combination
therapy with ritonavir, nelfinavir, or indinavir
were changed to ritonavir-saquinavir-hgc 400-
400 mg twice/day plus nevirapine 200 mg
twice/day with or without NRTIs.107 Viral load
ranged from 3.55–5.90 log copies/ml.  Ninety
percent of patients achieved viral load
suppression to fewer than 500 copies/ml for 6
months after the change in therapy.
Thirteen patients receiving regimens
containing indinavir or ritonavir were changed to
ritonavir-saquinavir-hgc plus nevirapine or
delavirdine plus a new NRTI when they failed
therapy.108 The mean viral load at switch was
31,000 copies.  After 6 months, 85% of patients
taking the salvage regimen had viral loads below
400 copies/ml.  Nine of 11 had viral loads below
25 copies/ml.
The combination was much less effective as
salvage therapy in another study.  Sixty-seven
patients failing indinavir-containing regimens
were treated with ritonavir-saquinavir with or
without one or two NRTIs.109 Only 8/54 and 2/34
patients had undetectable viral loads (< 500
copies/ml) at 1–2 and 5–6 months, respectively.
This poor response may have been secondary to
low CD4 counts (27 cells/mm3) and high viral
load (5.1 log copies/ml) at study entry.  These
studies suggest that ritonavir-saquinavir in
combination with or without NRTIs may be an
effective salvage regimen particularly when given
early after virologic failure of a PI-containing
regimen.
Nelfinavir-Saquinavir
In one of three studies assessing this
combination, 157 PI-naïve patients (CD4 count
301 cells/mm3, viral load 4.8 log copies/ml)
received one of four regimens:  saquinavir-sgc
1200 mg 3 times/day with two NRTIs; nelfinavir
750 mg 3 times/day with two NRTIs; saquinavir-
sgc 800 mg 3 times/day plus nelfinavir 750 mg 3
times/day and two NRTIs; and saquinavir-sgc 800
mg 3 times/day plus nelfinavir 750 mg 3
times/day without NRTIs.97 After 32 weeks of
treatment, 70%, 55%, 83%, and 69% of patients,
respectively, had viral loads below 400 copies/ml.
Mean reductions in viral load at 32 weeks were
2.48, 2.23, 2.46, and 2.39 log copies/ml,
respectively.  Median increases in CD4 count at
32 weeks were 92, 73, 134, and 161 cells/mm3,
respectively.
Nelfinavir 750 mg 3 times/day plus saquinavir-
sgc 800 mg 3 times/day was studied in 14
patients with a median baseline CD4 count of
327 cells/mm3 and viral load of 4.60 log
copies/ml.98 After 11 months of treatment 90%
(9/10) of patients had an undetectable viral load
(< 500 copies/ml) with a median decrease of 2.25
log copies/ml, and median increase in CD4 count
of 172 cells/mm3.
A large study is currently under way involving
825 PI-naïve patients treated with saquinavir-sgc
1200 mg 3 times/day plus one new NRTI;
saquinavir-sgc 1600 mg 3 times/day plus one new
NRTI; or saquinavir-sgc 1200 mg twice/day plus
nelfinavir 1250 mg twice/day and one new
NRTI.110 Eight-week results for the first 120
patients show that 62%, 65%, and 51% of
patients, respectively, had viral loads below 400
copies/ml.  Mean decreases in viral loads were
2.2, 2.2, and 1.9 log copies/ml, respectively.
Mean increases in CD4 counts were 114, 89, and
117 cells/mm3, respectively.  Routine adminis-
tration of this dual-PI combination in PI-naïve
patients awaits the results of this and other
studies.
The combination of nelfinavir-saquinavir was
also evaluated as salvage therapy.  Twenty-five
patients who either failed therapy or were
intolerant to PI plus NRTIs were treated with
nelfinavir 1250 mg twice/day plus saquinavir-sgc
1000 mg twice/day and two NRTIs.111 Nineteen
patients with mean CD4 counts of 118 cells/mm3
and viral loads of 4.5 log copies/ml, respectively,
finished 24 weeks of treatment.  The mean
decrease in viral load and increase in CD4 count
were 1.6 log copies/ml and 140 cells/ml,
respectively.  After 24 weeks,viral load was below
500 copies/ml in 45% of patients and below 40
copies/ml in 35%.
Ten patients with a viral load greater than 3.40
log copies/ml after more than 24 weeks of an
indinavir-containing combination were salvaged
with nelfinavir 1250 mg twice/day plus
saquinavir-sgc 1200 mg twice/day plus abacavir
300 mg twice/day and an NRTI, and 10 received
nelfinavir-saquinavir-sgc plus abacavir plus
nevirapine 200 mg twice/day.112 Median baseline
CD4 count was 290 cells/mm3 and viral load 4.33
log copies/ml.  At 20 weeks median decreases in
viral load were 0.59 and 2.67 log copies/ml,
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respectively.  Only one of seven patients in group
1 achieved a viral load below 50 copies/ml,
compared with seven of nine in group 2.  The
combination of nelfinavir and saquinavir-sgc,
particularly in combination with an NRTI or
NNRTI, is a salvage therapy option in patients
with extensive antiretroviral experience.
Indinavir-Nelfinavir
The pharmacokinetics, safety, and efficacy of
indinavir 1000 mg-nelfinavir 750 mg twice/day
were studied in 18 PI-naïve patients (median
CD4 count 259 cells/mm3, median viral load 4.70
log copies/ml).113 After 24 weeks of treatment,
viral load was below 400 copies/ml in 61% of
patients and below 50 copies/ml in 55%.  The
median increase in CD4 count over 24 weeks was
133 cells/mm3.  Indinavir trough levels were not
significantly different from levels from historic
monotherapy trials (205 nM for combination
therapy vs 251 nM for monotherapy).  Nelfinavir
trough levels, however, differed by a factor of 2;
combination therapy levels (750 mg twice/day)
were 0.7 mg/L and monotherapy levels (750 mg 3
times/day) were 1.5 mg/L.  The investigators
suggested that a higher nelfinavir dosage be
tested, and this combination requires further
study before is can be prescribed routinely in
clinical practice.
Ritonavir-Nelfinavir
Twenty PI-naïve patients (median baseline CD4
count 325 cells/mm3, viral load 4.51 log
copies/ml) received ritonavir 400 mg twice/day
plus nelfinavir 750 or 500 mg twice/day.114 After
16 weeks, 4/10 patients receiving 500 mg and
6/10 receiving 750 mg had undetectable viral
loads (< 400 copies/ml), with a mean decrease of
2.2 and 2.7 log copies/ml, respectively.  Mean
increases in CD4 counts were 202 and 37
cells/mm3, respectively.
Indinavir-Ritonavir
Twenty-four patients were treated with
indinavir 400 mg twice/day plus ritonavir 400 mg
twice/day plus stavudine and lamivudine.115
Group A consisted of 12 patients treated with
ritonavir-saquinavir, stavudine, and lamivudine
for more than 6 months who maintained a viral
load below 400 copies/ml.  Group B were
treatment naïve with a mean viral load of 4.82
log copies/ml.  At 36 weeks viral loads were
below 400 copies/ml in all group A patients.  At
12 weeks they were below 400 copies/ml in 10/12
group B patients.  The authors suggested that the
increase in indinavir levels in the presence of
ritonavir allows for twice/day dosing of indinavir
and eliminates the requirement that indinavir be
taken without food.  They also suggested that a
lowered maximum concentration for indinavir
might decrease the frequency of nephrolithiasis.
Further study of this combination is required.
Summary
Clinicians who care for HIV-infected patients
now have many options when selecting a PI-
containing antiretroviral regimen.  A patient’s
symptoms, the toxicity profile of an individual
agent, and the likelihood of a patient adhering to
a dosing schedule of 3 times/day must be taken
into account.  Dual-PI regimens have demonstrated
efficacy and their principal indication is as
second-line therapy at the present time.  Adverse
reactions to and metabolic complications with
PIs will become more important as experience
grows.  Thanks to the efficacy of PIs, more
attention will be paid to managing complications
that occur as a result of their prolonged
administration to extend the lives of HIV-infected
patients.
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